A bold move is underway as buyout firms strategize a remarkable £1.5 billion acquisition of Spire Healthcare Group, the largest private hospital operator in the UK. This potential takeover could lead to Spire becoming yet another company to exit the FTSE-250 index and leave the London stock market behind.
According to Sky News, several private equity firms, notably Bridgepoint and Triton Partners, are currently in discussions regarding bids for Spire, which operates nearly 40 of the UK's most prominent private hospitals. Sources within the City indicate that these two firms are part of a larger group of interested parties preparing offers before a deadline set by the company's advisors this week.
Additionally, Advent International and Bain Capital have reportedly reached out to Rothschild, who is overseeing the process, although they are not anticipated to advance further in this bidding war.
Spire's board, chaired by Sir Ian Cheshire—a respected figure who previously led B&Q's parent company, Kingfisher, and now heads the commercial property group Land Securities—appears eager to move forward with discussions with potential bidders in the near future.
If negotiations proceed as expected, a deal could be finalized within the upcoming months, according to insider information shared over the weekend. Furthermore, other financial investors and international trade buyers are believed to be involved in this process, which was catalyzed by pressure from significant shareholders.
Interestingly, Bridgepoint’s involvement is particularly noteworthy due to its previous ownership of Oasis Dental Care, a notable dental chain during the tenure of Justin Ash, who currently serves as Spire's CEO. Meanwhile, Triton Partners has established itself as a key player in the healthcare sector, owning assets like Pharmanovia, a specialized prescription medicine producer.
In addition to operating a vast network of hospitals, Spire manages over 50 clinics, medical centers, and consulting facilities throughout the UK. It holds the position as the leading provider of hip and knee surgeries in the nation. The company also runs a series of private GP practices and delivers occupational health services to hundreds of businesses.
With a workforce comprising nearly 9,000 consultants and thousands of staff members, Spire provided care to more than 1.3 million patients in 2024. Major investors in the company have been advocating for decisive corporate actions aimed at reversing its declining share price, including exploring strategies to unlock value from its extensive property portfolio, much of which it owns outright.
After a report from Sky News last September, Spire confirmed that it is "actively evaluating actions that could drive long-term sustainable shareholder value." The company reiterated in December that it has started discussions with various parties regarding a range of potential strategies, possibly including the sale of the company, value generation from its hospital properties, and a heightened focus on private payers.
In a trading update released that same month, Spire projected that its full-year adjusted earnings before interest, tax, depreciation, and amortization would fall at the lower end of the anticipated range of £270 million to £285 million. While private hospitals have increasingly been allocated to handle routine operations for NHS patients, financial limitations have constrained the volume of these procedures.
For additional insights from Sky News:
- TalkTalk increases efforts to shed consumer and wholesale divisions.
- An intriguing personal finance story begins with a missing phone, unveiling deeper relationship issues.
- A thought-provoking perspective on how one individual has dominated discussions at Davos.
Founded in 2007 when BUPA divested its hospitals division to Cinven, a private equity firm, Spire Healthcare Group has evolved significantly over the years. Mediclinic Group, a South African private healthcare provider established in 1983, currently holds a 29.9% stake in Spire.
In 2021, some of Spire's key shareholders dismissed a 250p-per-share offer from Ramsay Healthcare of Australia, citing it as undervaluing the business. Over the past year, Spire's stock has declined by over 23%, closing at 178.2p on Friday, which places its market capitalization just shy of £725 million. Any prospective bid will need to offer a substantial premium over this valuation to gain the support of major investors.
As of now, representatives from Spire, Advent International, Bain Capital, Bridgepoint, and Triton have chosen not to comment on the unfolding situation.
